Irlab Therapeutics Ab Class A · OMXSTO:IRLAB_A
Irlab Therapeutics Ab Class A — Q3 2025 Earnings Presentation
24 slides from Irlab Therapeutics Ab Class A's earnings presentation, Oct 1, 2025
Slide 1: World leader - developing new treatments for Parkinson's disease
World leader - developing new treatments for Parkinson's disease IRLAB, Q3 2025 ©2025 IRLAB Therapeutics AB (publ), All rights reserved
Slide 2: Disclaimer
Disclaimer This document, “IRLAB Therapeutics” (the “Presentation”), has been prepared by IRLAB Therapeutics AB (publ) (“IRLAB”) and is provided for informational purposes only. All information in this Presentation has been compiled in good faith by IRLAB. Neither IRLAB nor any of its directors, emp
Slide 3: Today's agenda
Today’s agenda 1 News in the period Kristina Torfgård, CEO 4 Concluding remarks 2 R&D update Nicholas Waters, EVP Head of R&D 3 Financials 5 Q&A session Kristina Torfgård, CEO ©2025 IRLAB Therapeutics AB (publ), All rights reserved 3
Slide 4: Key highlights in and after Q3 2025
Key highlights in and after Q3 2025 IRL757 progresses according Clinical trial application for Parkinson’s study submitted to EMA - to plan – fully funded additional USD 4 million received for the IRL757 study funded by MSRD through clinical PoC New patent granted for mesdopetam in China – market ex
Slide 5: R&D update
am | TRLAB It R&D update
Slide 6: Mesdopetam
Mesdopetam IRL790 Treating levodopa-induced dyskinesias (PD-LIDs) through a novel mechanism – Dopamine D3 receptor antagonism ©2025 IRLAB Therapeutics AB (publ), All rights reserved
Slide 7: LIDs market characteristics - Q3 update
LIDs market characteristics - Q3 update Key market characteristics and opportunity • Market research shows that mesdopetam has great potential in the large group of individuals who currently cannot be treated for their levodopa-induced dyskinesias • 3.4 to 4.2 million people worldwide live without t
Slide 8: Among patients experiencing troublesome/disabling dyskinesia only some receive treatment
Among patients experiencing troublesome/disabling dyskinesia only some receive treatment – leaving most with no option ≈ 21% ≈ 77.5 % of the PD population of all patients experiences with troublesome Target population in the troublesome/disabling dyskinesia are mesdopetam development dyskinesia untr
Slide 9: Mesdopetam fills the gap between current levodopa based and invasive treatments
Mesdopetam fills the gap between current levodopa based and invasive treatments PD Disease severity Pharmacological treatments Invasive treatments Levodopa adjustments + other Produodopa Duodopa DBS (120 kUSD (75-125 kUSD (65 kUSD) concomitant treatments 31 kGBP/yr) 28 kGBP/yr) Mesdopetam For indivi
Slide 10: Pirepemat
Pirepemat IRL752 • A treatment to reduce falls in Parkinson’s (PD-Falls) • Full program from preclin through a randomized, placebo- controlled dose-finding Phase IIb clinical trial completed ©2025 IRLAB Therapeutics AB (publ), All rights reserved
Slide 11: Pirepemat provides significant reduction of fall rate at optimal plasma concentrations
Pirepemat provides significant reduction of fall rate at optimal plasma concentrations • Phase IIb study in patients Prespecified analyses showed • Highly clinically meaningful with a history of frequent that a medium plasma and statistically significant falls concentration range effect (p<0.05 vs.
Slide 12: Development update Q3
Development update Q3 • Strengthened development plan in place • Development of large-scale manufacturing method initiated • Preparations of a clinical study to optimize individual dosage • React–PD study results accepted for presentation at AD/PD 2026 Congress • Pan-European expert group is prepari
Slide 13: IRL757 – treatment of apathy
IRL757 – treatment of apathy Apathy: loss of initiative, interest, and emotional expression/responsiveness • A novel first-in-class treatment for apathy in neurological disorders Addressable population: 2-7 million people ©2025 IRLAB Therapeutics AB (publ), All rights reserved
Slide 14: IRL757 project progress in Q3
IRL757 project progress in Q3 IRL757 has the potential to be the first drug in a new class to treat apathy in Parkinson’s and other neurological disorders • Funding to conduct the Phase I (SAD & MAD) study with IRL757 is secured through the Michael J. Fox Foundation • Collaboration with MSRD/Otsuka
Slide 15: Preclinical projects
Preclinical projects IRL942 Clinical candidate - Improve cognitive function IRL1117 Clinical candidate - Once-daily oral treatment of Parkinson’s without troublesome complications ©2025 IRLAB Therapeutics AB (publ), All rights reserved
Slide 16: IRL942 project progress in Q3
IRL942 project progress in Q3 IRL942 • Has the potential to be the first drug in a new class to improve the cognitive function in people living with Parkinson’s and other neurological disorders Status • GMP manufacturing of the drug substance and development of the method for drug product production
Slide 17: IRL1117 – potential to be the first drug in a new class to treat Parkinson's
IRL1117 – potential to be the first drug in a new class to treat Parkinson’s project progress in Q3 IRL1117 • A potent dopamine D1 and D2 receptor agonist with potential to replace levodopa • Long-term studies show that IRL1117 provides full anti-Parkinson's effect without activating genes linked to
Slide 18: Financial highlights Q3 2025
Financial highlights Q3 2025
Slide 19: Financial highlights
Financial highlights • Cash position SEK 110 million. • External clinical cost continues to decrease. • Partnering costs have increased and will remain quite high as the IRL757 study advances. • Increased cost control will be maintained in the coming quarters, with a focus on the IRL757 study, retai
Slide 20: Financial summary
Financial summary Q1-Q3 Q1-Q3 2025 2024 Net sales, SEK 42.7m 51.8 Operating profit, SEK - 71.5m - 72.1m Earnings per share before and after dilution, SEK - 1.42 - 1.50 Cash and cash equivalents, SEK 110.1m 90.4m Cash flow from operating activities, SEK - 31.0m - 43.0m Average number of employees 31
Slide 21: Concluding remarks
am | TRLAB It Concluding remarks
Slide 22: World leading portfolio of development programs for Parkinson's disease
World leading portfolio of development programs for Parkinson’s disease Discovery Preclinical Phase I Phase IIa Phase IIb Phase III Next major event Parkinson’s disease levodopa- Phase III Mesdopetam induced dyskinesia (PD-LIDs) 2026: ready (IRL790) D3 antagonist Projected start of Phase III study P
Slide 23: Value creation milestones over the next 12-18 months
Value creation milestones over the next 12-18 months • BD activities Mesdopetam • Initiation of the Phase III program • Decision on next step – prepare for dose Pirepemat optimization study • BD activities • Start the study in PD-apathy (Phase Ib safety IRL757 and efficacy signal finding) • IRL942:
Slide 24: Contact
Contact: Kristina Torfgård, CEO, kristina.torfgard@irlab.se Nicholas Waters, EVP and Head of R&D, nicholas.waters@irlab.se Roy Jonebrant, interim CFO, roy.jonebrant@irlab.se IRLAB discovers and develops a portfolio of transformative treatments for all stages of Parkinson’s disease. The company origi